id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2660-0006,FDA,FDA-2015-E-2660,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T17:15:43Z,,0,0,0900006482434443
FDA-2015-E-2660-0005,FDA,FDA-2015-E-2660,Correction of Eligibility Letter for OBIZUR from FDA CDER to Lathrop and Gage LLP,Other,Letter(s),2016-01-11T05:00:00Z,2016,1,2016-01-11T05:00:00Z,,2016-01-11T19:07:24Z,,0,0,0900006481dfe2f2
FDA-2015-E-2660-0004,FDA,FDA-2015-E-2660,Correction of Eligibility Letter for OBIZUR from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-01-11T05:00:00Z,2016,1,2016-01-11T05:00:00Z,,2016-01-11T19:07:12Z,,0,0,0900006481dfe2ef